NEUROD1 and prostate carcinoma: For instance, research on NE transformation in prostate cancer indicates that the combination of TP53 and RB1 loss with the overexpression of MYCN, ASCL1, or NeuroD1 is necessary to achieve an appropriate NE phenotype [54].